BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs 2021;30:463-77. [PMID: 33678096 DOI: 10.1080/13543784.2021.1900821] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2022. [PMID: 36260350 DOI: 10.3322/caac.21759] [Reference Citation Analysis]
2 Gadaleta-Caldarola G, Rizzo A, Dadduzio V, Lombardi L, Gadaleta-Caldarola A, Infusino S, Cusmai A, Citrigno C, Palmiotti G. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Curr Oncol 2022;29:7925-31. [PMID: 36290903 DOI: 10.3390/curroncol29100626] [Reference Citation Analysis]
3 Li H, Ding H, Wang Y, Zhang F, Song Y, Qiu X, Pons J. Validated UPLC-MS/MS Method for Determination of Futibatinib and Its Pharmacokinetics in Beagle Dogs. Journal of Chemistry 2022;2022:1-7. [DOI: 10.1155/2022/8316403] [Reference Citation Analysis]
4 Zhu Q, Zhai S, Ge E, Li L, Jiao X, Xiong J, Zhu G, Xu Y, Qu J, Wang Z. Intrahepatic cholangiocarcinoma with gastric metastasis misdiagnosed as primary gastric cancer: A case report and literature review. Front Oncol 2022;12:997735. [DOI: 10.3389/fonc.2022.997735] [Reference Citation Analysis]
5 Rizzo A, Carloni R, Ricci AD, Di Federico A, Guven DC, Yalcin S, Brandi G. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. JPM 2022;12:1247. [DOI: 10.3390/jpm12081247] [Reference Citation Analysis]
6 Cheng C, Chen C, Wu C. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life 2022;12:829. [DOI: 10.3390/life12060829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Song H, Huang Y, Jiang X. Mutation spectrum associated with metastasis of advanced cholangiocarcinoma. J Int Med Res 2022;50:3000605221102080. [PMID: 35726602 DOI: 10.1177/03000605221102080] [Reference Citation Analysis]
8 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
9 Sahu R, Sharma P, Kumar A. An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. J Gastrointest Cancer 2022. [PMID: 35023010 DOI: 10.1007/s12029-021-00728-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zhang Z, Wang Z, Huang Y. A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning. Front Oncol 2021;11:687904. [PMID: 34557406 DOI: 10.3389/fonc.2021.687904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]